Novartis presents first-of-its-kind histology data with iscalimab (CFZ533) suggesting the extended survival of transplanted organs may be possible

    NEXT STORY
    Beta Bionics and Zealand Pharma announce superior glycemic control in Phase 2 home-use clinical trial testing the iLet™ bionic pancreas using dasiglucagion
    PREV STORY
    Innate Pharma enrolls first patient in IPH4102 TELLOMAK Phase II study
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Five Prime Therapeutics Presents Initial Clinical Trial Data from Phase 1/2 trial of Cabiralizumab in Pigmented Villonodular Synovitis (PVNS) at 2017 ASCO Annual Meeting

    SOUTH SAN FRANCISCO, Calif., June 04, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. ...

    author_avatar
    NASDAQ Market News

    Chi-Med Announces Phase III FALUCA Trial Results for Fruquintinib in Third-Line, Advanced Non-Small Cell Lung Cancer in China

    – Trial did not meet the primary endpoint of overall survival despite improvement in ...

    author_avatar
    NASDAQ Market News

    Infectious Disease Diagnostics Market Worth $23.17 Billion by 2027- Pre and Post COVID-19 Market Estimates by Meticulous Research®

    author_avatar
    NASDAQ Market News